Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04269031 · ClinicalTrials.gov registry record · Phase 1
A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT04269031 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 30 participants.
The verdict
NCT04269031, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase 1 study to assess the the safety, tolerability and pharmacokinetics (PK) of AZD2373, following subcutaneous (SC) administration of single ascending doses (SAD) of AZD2373 in healthy male subjects of African ancestry.
Interventions
- DRUG Placebo
- DRUG AZD2373 subcutaneous injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-02-13 |
| Est. Completion | 2021-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04269031
The ClinicalTrials.gov registry entry for NCT04269031 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04269031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04269031 about?
NCT04269031 is a clinical study titled "A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.". This is a Phase 1 study to assess the the safety, tolerability and pharmacokinetics (PK) of AZD2373, following subcutaneous (SC) administration of single ascending doses (SAD) of AZD2373 in healthy male subjects of African ancestry.
What is the current status of trial NCT04269031?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2020-02-13. Estimated completion is 2021-08-31.
What interventions are being tested in trial NCT04269031?
The interventions under investigation include: Placebo (DRUG), AZD2373 subcutaneous injection (DRUG).
Who is sponsoring clinical trial NCT04269031?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.